Henry Schein, Inc. (NASDAQ:HSIC) Director Sells $184,988.16 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the transaction, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. This represents a 9.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Henry Schein Stock Down 1.5 %

HSIC opened at $69.39 on Friday. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock’s fifty day moving average is $74.82 and its 200-day moving average is $72.61. The company has a market capitalization of $8.62 billion, a PE ratio of 28.56, a P/E/G ratio of 2.13 and a beta of 0.90.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the prior year, the firm posted $0.66 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. On average, equities analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HSIC. Barrington Research restated an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their price objective on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Mizuho began coverage on Henry Schein in a research report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price objective for the company. UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, February 26th. Finally, Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and boosted their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Six investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.10.

Institutional Trading of Henry Schein

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC raised its stake in shares of Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after buying an additional 143 shares in the last quarter. Guggenheim Capital LLC raised its position in shares of Henry Schein by 2.5% during the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company’s stock worth $445,000 after purchasing an additional 159 shares during the period. CIBC Asset Management Inc raised its position in shares of Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock worth $1,235,000 after purchasing an additional 169 shares during the period. Studio Investment Management LLC raised its position in shares of Henry Schein by 3.8% during the third quarter. Studio Investment Management LLC now owns 4,674 shares of the company’s stock worth $341,000 after purchasing an additional 172 shares during the period. Finally, Metis Global Partners LLC raised its position in shares of Henry Schein by 4.7% during the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock worth $291,000 after purchasing an additional 187 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.